Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$4.6 million.

  • Kyntra Bio's Change in Account Payables fell 53379.12% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year increase of 6960.24%. This contributed to the annual value of $14.5 million for FY2024, which is 19354.13% up from last year.
  • According to the latest figures from Q3 2025, Kyntra Bio's Change in Account Payables is -$4.6 million, which was down 53379.12% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Kyntra Bio's Change in Account Payables ranged from a high of $69.0 million in Q4 2022 and a low of -$61.3 million during Q2 2023
  • For the 5-year period, Kyntra Bio's Change in Account Payables averaged around $2.0 million, with its median value being -$344000.0 (2021).
  • Data for Kyntra Bio's Change in Account Payables shows a peak YoY increase of 349385.42% (in 2022) and a maximum YoY decrease of 902941.18% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Kyntra Bio's Change in Account Payables stood at $1.9 million in 2021, then skyrocketed by 3493.85% to $69.0 million in 2022, then tumbled by 102.11% to -$1.5 million in 2023, then skyrocketed by 1693.48% to $23.2 million in 2024, then tumbled by 119.87% to -$4.6 million in 2025.
  • Its Change in Account Payables stands at -$4.6 million for Q3 2025, versus $3.1 million for Q2 2025 and -$24.8 million for Q1 2025.